Chinese Medical Journal最新文献

{"title":"Z-DNA-binding protein 1-mediated programmed cell death: Mechanisms and therapeutic implications.","authors":"Yuwei Huang, Lian Wang, Yanghui Zhu, Xiaoxue Li, Yingying Dai, Gu He, Xian Jiang","doi":"10.1097/CM9.0000000000003737","DOIUrl":"10.1097/CM9.0000000000003737","url":null,"abstract":"<p><strong>Abstract: </strong>Programmed cell death (PCD) is characterized as a cell death pathway governed by specific gene-encoding requirements, plays crucial roles in the homeostasis and innate immunity of organisms, and serves as both a pathogenic mechanism and a therapeutic target for a variety of human diseases. Z-DNA-binding protein 1 (ZBP1) functions as a cytosolic nucleic acid sensor, utilizing its unique Zα domains to detect endogenous or exogenous nucleic acids and its receptor-interacting protein homotypic interaction motif (RHIM) domains to sense or bind specific signaling molecules, thereby exerting regulatory effects on various forms of PCD. ZBP1 is involved in apoptosis, necroptosis, pyroptosis, and PANoptosis and interacts with molecules, such as receptor-interacting protein kinase 3 (RIPK3), to influence cell fate under various pathological conditions. It plays a crucial role in regulating PCD during infections, inflammatory and neurological diseases, cancers, and other conditions, affecting disease onset and progression. Targeting ZBP1-associated PCD may represent a viable therapeutic strategy for related pathological conditions. This review comprehensively summarizes the regulatory functions of ZBP1 in PCD and its interactions with several closely associated signaling molecules and delineates the diseases linked to ZBP1-mediated PCD, along with the potential therapeutic implications of ZBP1 in these contexts. Ongoing research on ZBP1 is being refined across various disease models, and these advancements may provide novel insights for studies focusing on PCD, potentially leading to new therapeutic options for related diseases.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2.5D multimodal MRI improves convolutional neural networks performance in predicting the IDH mutation status of adult diffuse gliomas.","authors":"Jun Qiu, Junjie Li, Zhizheng Zhuo, Yunyun Duan, Minghao Wu, Min Guo, Jun Sun, Ying Jin, Jinyuan Weng, Xiaodong Gong, Xing Liu, Yaou Liu","doi":"10.1097/CM9.0000000000003761","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003761","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144944997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Baseline characteristics, in-hospital outcomes and time variances of intracerebral hemorrhage in China: Based on a national, large-scale registry cohort.","authors":"Guangshuo Li, Kaijiang Kang, Hongqiu Gu, Kaixuan Yang, Zixiao Li, Xingquan Zhao","doi":"10.1097/CM9.0000000000003772","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003772","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945030","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging technologies for septal reduction therapy in hypertrophic cardiomyopathy.","authors":"Yunye Zhang, Xingwei Zhang, Zhihong Zhao","doi":"10.1097/CM9.0000000000003781","DOIUrl":"10.1097/CM9.0000000000003781","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12487903/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945048","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tegoprazan-based versus esomeprazole-based triple therapy plus bismuth for first-line Helicobacter pylori eradication: A nationwide, multicenter, double-blind, double-dummy, randomized controlled trial.","authors":"Zhiqiang Song, Weihong Wang, Peng Li, Xiuli Zuo, Yin Zhu, Ye Chen, Xiaolan Zhang, Bin Lyu, Rong Lin, Yiqi Du, Cheng Lan, Hao Wu, Weixing Chen, Yanqing Ye, Huizhen Fan, Aijun Liao, Honghui Chen, Chengxia Liu, Zhenyu Zhang, Wen Wang, Zhimin Suo, Xiaoan Li, Qin Du, Xing Li, Feng Pan, Jianhua Tang, Min Xu, Xiongxiang Liu, Pengyuan Zheng, Huixin Chen, Ling Du, Jiayin Lu, Chun Feng, Wensheng Pan, Hong Wang, Zhirong Zeng, Jinhai Wang, Shengxiang Lyu, Dunju Liu, Shiming Yang, Liangping Li, Liya Zhou","doi":"10.1097/CM9.0000000000003780","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003780","url":null,"abstract":"<p><strong>Background: </strong>Although triple therapy plus bismuth (TTPB), comprising a proton pump inhibitor (PPI), two antibiotics, and bismuth, is widely used to eradicate Helicobacter pylori (H. pylori), eradication rates have been suboptimal. Potassium-competitive acid blockers (P-CABs) offer stronger and more stable gastric acid inhibition compared to PPIs. This study aimed to compare the efficacy, safety, and compliance of tegoprazan-based TTPB (TACB) vs. esomeprazole-based TTPB (EACB) in treatment-naïve patients with H. pylori infection.</p><p><strong>Methods: </strong>In this nationwide, multicenter, double-blind, double-dummy, randomized controlled trial conducted from October 2022 to September 2023 across 41 centers in China, 561 eligible patients with H. pylori infection were randomized (1:1) to receive either TACB (tegoprazan 50 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth 220 mg) or EACB (esomeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, and bismuth 220 mg), all administered twice daily for 14 days. H. pylori eradication was assessed using the 13C-urea breath test at 4-8 weeks post-treatment. The primary endpoint was eradication rate based on the full analysis set (FAS). Statistical analysis included the chi-squared tests, with a predefined non-inferiority margin of -10%.</p><p><strong>Results: </strong>In the FAS population, eradication rates were 93.5% (95% confidence interval [CI]: 89.9-96.1%) in the TACB group and 86.4% (95% CI: 81.9-90.2%) in the EACB group. The between-group difference was 7.0% (95% CI: 2.1-12.0%), indicating that tegoprazan-based TTPB was non-inferior to esomeprazole-based TTPB. Furthermore, superiority tests found a significantly higher eradication rate in tegoprazan group compared with esomeprazole group (P = 0.006). Similar results were observed in the per-protocol set. The incidence of treatment-emergent adverse events was comparable between groups (75.5% in TACB vs. 73.4% in EACB), with most events being mild and transient. Compliance was high in both groups (98.4% vs. 98.8%).</p><p><strong>Conclusion: </strong>TACB was non-inferior to EACB in H. pylori eradication efficacy, with similar safety and compliance profiles in Chinese treatment-naïve patients.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov identifier: NCT05577468.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of NLRP3 genetic variant rs10754555 with early-onset coronary artery disease.","authors":"Lingfeng Zha, Chengqi Xu, Mengqi Wang, Shaofang Nie, Miao Yu, Jiangtao Dong, Qianwen Chen, Tian Xie, Meilin Liu, Fen Yang, Zhengfeng Zhu, Xin Tu, Qing K Wang, Zhilei Shan, Xiang Cheng","doi":"10.1097/CM9.0000000000003791","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003791","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945077","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Caffeic acid tablets plus high-dose dexamethasone versus placebo plus high-dose dexamethasone in patients with newly diagnosed immune thrombocytopenia: A multicenter, double-blind, randomized, controlled, phase 2 trial.","authors":"Ruting Wang, Yang Liu, Ruixue Wang, Junying Cao, Yunliang Hao, Taiwu Xiao, Zheng Yu, Wenzheng Yu, Xiaoxia Chu, Xuehong Ran, Chuansheng Zhu, Ruirong Xu, Jing Xiao, Xiuzhi Deng, Hao Zhang, Zhencheng Wang, Guoqiang Liu, Ming Hou, Yu Hou","doi":"10.1097/CM9.0000000000003783","DOIUrl":"https://doi.org/10.1097/CM9.0000000000003783","url":null,"abstract":"<p><strong>Background: </strong>Standard initial therapy with intensive glucocorticoids requires further optimization due to high relapse rates and unsatisfying long-term outcomes in patients with primary immune thrombocytopenia (ITP). Caffeic acid (CA) has been reported to increase platelet counts in thrombocytopenia. This study investigated the efficacy and safety of CA tablets plus high-dose dexamethasone (HD-DXM) as a novel initial treatment for adults with newly diagnosed ITP.</p><p><strong>Methods: </strong>This multicenter, double-blind, randomized, placebo-controlled trial was conducted from July 1, 2015 to February 28, 2022 in fourteen tertiary medical hospitals in China. Eligible patients aged ≥18 years with newly diagnosed, treatment-naïve primary ITP who had a baseline platelet count of <30 × 109/L were enrolled during routine outpatient visits. Participants were randomly assigned in a 1:1 ratio to receive either CA tablets (0.3 g three times daily for 12 weeks) plus HD-DXM (40 mg/day for four days, repeated with a 10-day interval) or placebo plus HD-DXM. The primary endpoint was a 24-week sustained response (SR), defined as the maintenance of a platelet count higher than 30 × 109/L, at least doubling of the baseline platelet count, and an absence of bleeding. The Chi-squared test and Kaplan-Meier method were used to compare the 24-week SR and duration of response (DOR) between groups.</p><p><strong>Results: </strong>The intention to treat analysis included 214 patients who received at least one-dose of allocated treatments (median [Q1-Q3] age, 45 [32-55] years; 154 females [72.0%]). At week 24, 56.5% (61/108) of participants in the CA plus HD-DXM group achieved SR, which was significantly higher than 29.2% (31/106) of those in the placebo plus HD-DXM group (odds ratio [OR] 3.14; 95% confidence interval [CI] 1.78-5.53; P <0.0001). Adding CA to HD-DXM resulted in a longer DOR than the placebo (hazard ratio 0.50; 95% CI 0.34-0.74; P = 0.00028). The most commonly observed adverse events (AEs) in both groups were gastrointestinal symptoms, anxiety or mood disorders, and fatigue, without statistically significant differences. No grade 4 or worse AEs or death occurred.</p><p><strong>Conclusion: </strong>This study confirms CA tablets plus HD-DXM as a well-tolerated, cost-effective, and optimized initial therapy for patient with newly-diagnosed ITP to conveniently maintain platelet counts and avoid early relapse.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov. NCT02556814.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144945008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends and sex disparities in the burden of urolithiasis in 204 countries and territories, 1990-2021.","authors":"Junjiong Zheng, Qihang Zhang, Jie Zhang, Yuhui Yao, Li Chen, Yunfei Liu, Yi Song, Tianxin Lin, Guohua He","doi":"10.1097/CM9.0000000000003622","DOIUrl":"10.1097/CM9.0000000000003622","url":null,"abstract":"<p><strong>Background: </strong>Urolithiasis is a widespread disease with a high prevalence worldwide. This study aims to evaluate the disease burden of urolithiasis and its trends from 1990 to 2021 globally, based on the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2021 database.</p><p><strong>Methods: </strong>The numbers and age-standardized rates (ASRs) of incidence, disability-adjusted life years (DALYs), and mortality of urolithiasis were extracted from GBD 2021 to represent the disease burden. Joinpoint regression analyses were conducted to assess the temporal trends in the burden of urolithiasis. The male-to-female ASR ratio indices were used to evaluate sex disparities. Additionally, we explored the relationship between the ASR ratio and the sociodemographic index (SDI).</p><p><strong>Results: </strong>The total numbers of incidence, DALY, and mortality of urolithiasis were 105,983,780 cases (95% uncertainty interval [UI] = 88,349,356-128,645,155 cases), 693,444 cases (95% UI = 567,765-850,490 cases), and 17,672 cases (95% UI = 13,932-21,241 cases), respectively, in 2021. There is an increasing trend in the number of these measures globally, whereas the ASRs have decreased over the past 30 years. The age-standardized incidence rate (ASIR) and age-standardized mortality rate (ASMR) were significantly higher in males than in females in 2021. The sex disparities in the age-standardized DALY rate (ASDR) and ASMR of urolithiasis were negatively correlated with the SDI. In 2021, the ASIR of urolithiasis was 964.70 (95% UI = 801.26-1175.09) per 100,000 people in China, which is much lower than the global average (1242.84 [95% UI = 1034.94-1506.99] per 100,000 people). Compared with the global average, a more pronounced decline in ASIR was observed in China from 1793.16 (1446.0-2235.14) in 1990 to 964.70 (801.26-1175.09) per 100,000 people in 2021.</p><p><strong>Conclusions: </strong>Urolithiasis poses a significant healthcare burden worldwide. More robust global and national strategies are warranted to address the prevention and treatment, especially in low SDI countries and regions.</p>","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1973-1983"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144648651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimization of biosafety laboratory management via an AI-driven intelligent system.","authors":"Chang Qi, Anqi Lin, Anghua Li, Peng Luo, Shuofeng Yuan","doi":"10.1097/CM9.0000000000003760","DOIUrl":"10.1097/CM9.0000000000003760","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":""},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144882224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"2024 Chinese expert consensus on clinical utilization of laparoscopic and endoscopic cooperative surgery for gastric tumors.","authors":"Liang Shang, Ziyu Li, Pinghong Zhou, Zhenning Wang, Leping Li","doi":"10.1097/CM9.0000000000003639","DOIUrl":"10.1097/CM9.0000000000003639","url":null,"abstract":"","PeriodicalId":10183,"journal":{"name":"Chinese Medical Journal","volume":" ","pages":"1897-1903"},"PeriodicalIF":7.3,"publicationDate":"2025-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12369778/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}